New drugs and drug combinations are being developed to improve the treatment of metastatic melanoma, as researchers have found secondary resistance to existing treatments like tyrosine kinase inhibitors (RTKs), especially those directed at activating BRAF mutations, CTLA4, and PD1 inhibitors. Here, CTLA4 is linked to metastatic melanoma.